Cameron Miranda
The laws and regulations surrounding gene editing differ across the world. While human genome editing is banned in most countries, the specific regulations vary. For example, in the United States, gene therapy is treated as a biological drug or device, and falls under the regulation of the FDA. In the European Union, genetically engineered foods are regulated, while in Muslim countries, the permissibility of human genome editing is influenced by Islamic law. In addition, the regulations for gene editing of animals and crops are under discussion in many countries, with 34 countries commercially allowing gene-edited crops and animals as of 2019.
| Characteristics | Values |
|---|---|
| Gene editing laws | Differ across countries |
| Gene therapy products | Treated as drugs and regulated differently |
| Gene editing in embryos | Allowed in at least 11 countries, banned in 19, and neutral in others |
| Liability for damages | Not clear |
| Ethical concerns | Exist regarding human germline and embryo editing |
| International collaboration | Needed for better global surveillance and standards |
| Private industry | Plays a role in the ecosystem of law, regulation, and biotechnology |
Explore related products
What You'll Learn
Embryo gene editing laws
Gene editing is a powerful technology that allows for genetic modifications in cells. However, its use in human embryos raises ethical concerns, such as the moral status of the embryo and the potential for creating "designer babies". As a result, embryo gene editing is banned in many countries, including through guidelines, laws, and regulations.
In 2018, a Chinese scientist announced that he had successfully edited the genomes of twin girls at the early embryo stage to confer resistance to HIV infection. This announcement caused international backlash, with many countries working to clarify regulations on germline gene editing. China sentenced the scientist, Jiankui He, to three years in prison and a fine of three million RMB Yuan in 2019 for violating Article 336 of the Criminal Law of the People's Republic of China, which prohibits engaging in medical activities without a license.
While there is no federal law banning germline gene editing in the United States, the Dickey-Wicker Amendment prevents federal funding for research involving the creation or destruction of human embryos. The US Food and Drug Administration (FDA) also does not allow federal funds to be used for research on germline gene therapy due to ethical concerns. However, private labs can conduct non-clinical human gene therapy research, but FDA approval is needed if the therapy is to be sold in the US.
In South Korea, the Bioethics and Biosafety Act (BioAct) does not specifically regulate gene editing. However, it provides regulations for research on humans and gene therapy research, which can be applied to gene editing. The Korean Pharmacopoeia Act and the Pharmaceutical Affairs Law also regulate clinical trials and the approval process for pharmaceuticals, respectively, which include gene therapy products.
A survey of 106 countries found that 96 have policy documents relevant to the use of genome editing in early-stage human embryos, gametes, or their precursor cells. Of these 96 countries, 23 prohibit germline genome editing research, 11 permit it, and six are indeterminate. Seventy-five of these countries prohibit the use of genetically modified in vitro embryos to initiate a pregnancy (heritable genome editing).
Constitutional Law Scholars: Experts in Democracy's Blueprint
You may want to see also
Explore related products
Country-specific differences
Gene editing laws vary across the world and are subject to different interpretations and regulations in each country. While human genome editing is banned in most countries, the nature and severity of penalties vary. For example, in 2019, a Chinese researcher, Jiankui He, was sentenced to three years in prison and fined 3 million RMB Yuan for his involvement in genome-edited babies. In contrast, similar behavior could result in up to 10 years of imprisonment in the UK and 20 years in France. China's response to this case included the promulgation of regulations to safeguard public health, national security, and public interest through effective management of the country's human genetic resources.
In South Korea, gene editing is not specifically regulated by the Bioethics and Biosafety Act (BioAct). However, if gene editing is used in research and treatment, the regulations for research on humans and gene therapy research come into play. Additionally, gene therapy products are considered drugs and are thus subject to the Korean Pharmacopoeia Act and the Pharmaceutical Affairs Law, which outlines the authority of the Food and Drug Safety Directorate.
The United States has not banned human genome editing, but it is under the vigilant watch of the Food and Drug Administration (FDA) and the National Institutes of Health (NIH). Any clinical trial proposals for germline alterations will be rejected by the Recombinant DNA Advisory Committee (RAC) of the NIH.
Some Muslim countries, where Islam is the official religion, shape their legislation on medical technologies and fertilization techniques to align with Islamic law. Their permissibility of human genome editing is guided by the Islamic Code of Medical and Health Ethics, Sharia (Islamic canonical law), and fatwas (non-binding advice from Muslim religious scholars).
The absence of explicit policy documents related to human germline or heritable genome editing in some countries may be attributed to various factors. These include the presence of other authoritative documents, commercial interests, lobbying by the scientific community, or a combination of these factors.
Socialism's Lawmaking: A Democratic Process
You may want to see also
Explore related products
Ethical and social repercussions
Gene editing technologies, such as CRISPR-Cas9, have raised concerns about ethical and social repercussions. The use of genome editing in human embryos has sparked debates about the moral status of the embryo and the potential consequences for future generations. As of 2014, about 40 countries discouraged or banned research on germline editing due to ethical and safety concerns.
One of the primary ethical concerns surrounding gene editing is the potential for misuse or abuse of the technology. Editing the human germline could lead to irreversible mutations and have serious consequences on the heredity of future generations. It might also affect the development of a fetus in unexpected ways or have unknown long-term side effects. There is also a risk of ""off-target effects" (edits in the wrong place) and "mosaicism" (when some cells carry the edit but others do not). As a result, many researchers and bioethicists argue that germline genome editing should not be used for clinical reproductive purposes until it is proven safe through extensive research.
The regulation of gene editing varies across different countries, leading to differing social and ethical repercussions. For example, in the case of the Chinese researcher He Jiankui, who edited the genes of two human embryos, the Chinese government sentenced him to three years of imprisonment and a fine. In contrast, similar behavior could result in up to 10 years of imprisonment in the UK and 20 years in France.
The differing regulatory approaches can also impact the progress of scientific research and the development of new treatments. For instance, in South Korea, the Bioethics and Biosafety Act (BioAct) does not specifically regulate "gene editing" but instead focuses on the regulations for research on humans and gene therapy research. On the other hand, the Korean Pharmacopoeia Act (KPA) and the Pharmaceutical Affairs Law (PAL) regulate clinical trials using pharmaceuticals, including gene therapy products, with stringent sanctions in place.
The social and ethical repercussions of gene editing are complex and multifaceted. While gene editing offers hope for families affected by devastating genetic diseases, it also raises concerns about equity and accessibility. Gene therapy may only be accessible to the wealthy due to its potentially high costs, and it could further widen the gap between the privileged and the underprivileged. Additionally, the widespread use of gene therapy may lead to a less accepting society, impacting how we perceive and value human diversity.
To address these ethical and social repercussions, ongoing public deliberation and debate are crucial. A "global observatory" on gene editing, as proposed by Sheila Jasanoff, could promote exchange across disciplinary and cultural divides, fostering a more informed and inclusive discussion on the social and ethical implications of gene editing.
The Three Laws of Planetary Motion: Kepler's Legacy
You may want to see also
Explore related products
Intellectual property rights
The use of gene-editing technologies in medicine and agriculture has raised ethical and policy concerns, including issues of intellectual property rights. Gene editing technologies, such as the CRISPR/Cas-9 system, often fall under the utility patent category, which grants the inventor the right to exclude others from making, using, or selling the invention. The first gene-editing therapy utilizing CRISPR/Cas-9 was approved by the Food and Drug Administration (FDA) in December 2023 as a treatment for sickle cell disease.
The history of the discovery and application of CRISPR/Cas-9 involves two prominent research teams battling for its intellectual property rights. Jennifer Doudna and Emmanuelle Charpentier of the University of California, Berkeley, and the University of Vienna obtained the original patent for general use. Meanwhile, Feng Zhang of the Massachusetts Institute of Technology (MIT)/Harvard/Broad Institute obtained the patent for use on eukaryotes, including plants and animals. The main issue over these rights is which team developed CRISPR/Cas-9 for the modification of eukaryotic genomes. The Broad Institute has prevailed in appeals, with the latest decision in February 2022 confirming their team was the first to invent the technology for modifying genomes in human cells.
The use of gene-editing techniques in plant breeding has also drawn legal and ethical discourses globally, with heterogeneous national regulatory approaches. Some countries, such as the European Union (EU) and New Zealand, have stringent regulations, while others like Canada and the United States are more gene-editing friendly. The European Commission has acknowledged concerns related to IP protection, particularly from breeders' and farmers' organizations, regarding access to patented genetic material.
The complex IP landscape surrounding gene-editing technologies can deter innovation and hinder cumulative research. Exclusive IP rights can encourage investment and research and development but may also restrict access to technology and genetic material. A government-administered patenting system has been proposed as a more transparent and legitimate alternative to ethical licensing, providing better security and greater legitimacy.
Understanding Actual Damages in Contract Law
You may want to see also
Explore related products
Civil liability for damages
Gene editing laws vary across the world, with some countries banning the practice while others regulate it. Genome editing on healthy human embryos is banned by guidelines, laws, and regulations in most countries. However, in 2019, the first criminal case involving genome-edited babies was sentenced in China, resulting in a three-year imprisonment and a fine for the researcher. This case highlighted the potential for irreversible damage to the human genome and the need for stricter regulations and global collaboration.
The development of gene therapy and the CRISPR-Cas9 method has sparked a global discussion about the ethical and legal implications of interfering with the human genome. While gene editing offers potential benefits, it also raises complex questions about civil liability for damages caused by gene editing, especially in the case of human embryos and reproductive cells.
The current lack of clear legal principles for compensatory liability in this area is a significant concern. Legal experts must address the potential legal problems that may arise from gene editing, such as the rights of individuals whose genomes have been modified and the possibility of children taking legal action against their parents for genetic modifications. The interpretation of traditional compensation structures and private law considerations, as seen in Polish law, may offer some insights.
Different countries have varying approaches to regulating gene editing. For example, South Korea's Bioethics and Biosafety Act (BioAct) does not specifically mention "gene editing" but includes regulations for research on humans and gene therapy. The Korean Pharmacopoeia Act and Pharmaceutical Affairs Law also impact gene editing by regulating clinical trials and the approval process for pharmaceuticals. In Russia, there is a need to amend civil acts, criminal law, and administrative law to establish clear procedures for informed consent and compensation for harm caused by genomic research.
As gene editing technology advances, it is crucial to develop effective and binding mechanisms to constrain its use and protect individuals' rights. A collaborative global network led by organizations like the World Health Organization (WHO) can help establish global standards for governance and oversight of human genome editing.
The First Presidential Veto: A Historical Perspective
You may want to see also
Frequently asked questions
Yes, gene-editing laws vary across the world.
No country currently permits heritable human genome editing. However, 11 countries allow the use of genetically modified in vitro embryos in laboratory research.
In the United States, gene therapy is regulated by the FDA and treated as a biological drug or device. The US also has the National Environmental Policy Act, which allows for public scrutiny of government decisions. In China, a researcher was sentenced to three years in prison and fined for his work on genome-edited babies. Following this incident, China introduced regulations to protect public health and national security regarding human genetic resources.
In Muslim countries, Islamic law can influence legislation on gene editing. For example, Bahrain's legislation stipulates that medical technologies must be used in a way that does not contradict Islamic law.
The Oviedo Convention, or the Convention on Human Rights and Biomedicine, protects the genetic constitution of individuals from unlawful interventions. The Cartagena Protocol on Biosafety is another international agreement that ensures the safe handling, transport, and use of living modified organisms.
